Pulse Biosciences Inc (PLSE) Q4 2025 Earnings Call Transcript

Why It Matters

Early commercial traction and regulatory approvals validate Pulse’s nanosecond PFA technology, positioning it for rapid growth in high‑value thyroid and cardiac ablation markets.

Key Takeaways

• First revenue recognized: $86,000 from limited market release
• FDA IDE approved pivotal atrial fibrillation study for NanoClamp AF
• Over 200 procedures completed across pilot and commercial programs
• Cash balance rose to $95.2 million, supporting study funding
• Stock-based compensation rose to $5.6 million, 38% expense increase

Pulse Analysis

Pulse Biosciences’ nanosecond pulse field ablation (NSPFA) distinguishes itself from thermal and microsecond PFA by delivering ultra‑short, high‑intensity electric bursts that ablate tissue without heating surrounding structures. This non‑thermal mechanism promises faster lesion creation, reduced collateral damage, and simplified workflow across multiple specialties, from thyroid to cardiac applications. As physicians seek minimally invasive alternatives that improve safety and procedural efficiency, NSPFA positions Pulse as a potential disruptor in markets traditionally dominated by radiofrequency and cryo‑ablation technologies.

The Q3 2025 call highlighted tangible clinical momentum: more than 200 patients have been treated in pilot programs, the PRECISE BTN thyroid study is over 40 % enrolled, and the NanoClamp AF surgical clamp received FDA IDE clearance with the first patient already treated. European feasibility studies reported ablation times as low as 50 seconds and favorable safety signals for both the cardiac clamp and the 360° catheter, which now includes 150 enrolled patients. These data reinforce the company’s claim that NSPFA can accelerate procedures while maintaining efficacy.

Financially, Pulse ended September with $95.2 million in cash, enough to fund the upcoming pivotal IDE studies without immediate dilution. Revenue remains modest at $86 k, reflecting the early stage of commercial rollout, while GAAP losses widened to $19.4 million due largely to stock‑based compensation and trial expenses. Management’s disciplined go‑to‑market plan—focusing on high‑utilization accounts before expanding headcount—aims to drive procedure volume and reimbursement traction. A strategic partnership in electrophysiology could accelerate adoption of the 360° catheter, potentially unlocking a multi‑billion‑dollar AF ablation market.